Technical issues hit Sanofi's supply of Apidra
Stock shortages Sanofi has reported a "temporary interruption" to its supply of Apidra ClikStar insulin cartridges, and Optiset and SoloStar insulin pens.
Sanofi has reported a "temporary interruption" to its supply of Apidra ClikStar insulin cartridges, and Optiset and SoloStar insulin pens. The shortages were caused by a "technical issue" at Sanofi's manufacturing site in Frankfurt, the manufacturer said, but stressed there was "no concern regarding Apidra itself" or its other insulins.
Sanofi expects wholesaler stocks of Apidra Optiset and SoloStar pens to be exhausted later this month, while stocks of Apidra ClikStar cartridges are anticipated to run out by late September or early October. The manufacturer expects to resume supply of the Solostar pen and ClikStar cartridges by December, but warned that it was "unlikely" to supply Optiset pens again before their withdrawal at the end of the year.
Apidra OptiClik cartridges and the Apidra solution for injection vials have not been affected by the problems.
Sanofi confirmed it had reserved a supply of the SoloStar pens, which it would make available "on a case-by-case basis" to patients who were only able to use Apidra insulin.
The manufacturer advised pharmacists to contact them in the first instance if they did not have the stocks to dispense a prescription for Apidra. Pharmacists can call Sanofi customer services on 0800 854 430 to check whether Apridra is available to order. Any other enquiries, including specific patient cases, can be directed to the manufacturer's medical information line on 01483 505 515. Alternatively, pharmacists can contact their local Sanofi diabetes account manager for information and support.